JP4672257B2 - エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 - Google Patents

エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 Download PDF

Info

Publication number
JP4672257B2
JP4672257B2 JP2003550783A JP2003550783A JP4672257B2 JP 4672257 B2 JP4672257 B2 JP 4672257B2 JP 2003550783 A JP2003550783 A JP 2003550783A JP 2003550783 A JP2003550783 A JP 2003550783A JP 4672257 B2 JP4672257 B2 JP 4672257B2
Authority
JP
Japan
Prior art keywords
treatment
carcinoid syndrome
formula
tumor
neuroendocrine tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003550783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511721A (ja
JP2005511721A5 (https=
Inventor
ジョン・デイビッド・ロサーメル
エリック・ハワード・ルービン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2005511721A publication Critical patent/JP2005511721A/ja
Publication of JP2005511721A5 publication Critical patent/JP2005511721A5/ja
Application granted granted Critical
Publication of JP4672257B2 publication Critical patent/JP4672257B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
JP2003550783A 2001-12-13 2002-12-12 エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 Expired - Fee Related JP4672257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34216701P 2001-12-13 2001-12-13
US41599002P 2002-10-04 2002-10-04
PCT/EP2002/014162 WO2003049734A1 (en) 2001-12-13 2002-12-12 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome

Publications (3)

Publication Number Publication Date
JP2005511721A JP2005511721A (ja) 2005-04-28
JP2005511721A5 JP2005511721A5 (https=) 2006-01-26
JP4672257B2 true JP4672257B2 (ja) 2011-04-20

Family

ID=26992855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003550783A Expired - Fee Related JP4672257B2 (ja) 2001-12-13 2002-12-12 エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用

Country Status (22)

Country Link
US (3) US20050020647A1 (https=)
EP (1) EP1463504B1 (https=)
JP (1) JP4672257B2 (https=)
KR (1) KR101010767B1 (https=)
CN (1) CN1602192A (https=)
AT (1) ATE330602T1 (https=)
BR (1) BR0214917A (https=)
CA (1) CA2468994A1 (https=)
CY (1) CY1105459T1 (https=)
DE (1) DE60212710T2 (https=)
DK (1) DK1463504T3 (https=)
ES (1) ES2266610T3 (https=)
HU (1) HUP0402537A3 (https=)
IL (1) IL162166A0 (https=)
MX (1) MXPA04005712A (https=)
NO (1) NO332773B1 (https=)
NZ (1) NZ533378A (https=)
PL (1) PL209147B1 (https=)
PT (1) PT1463504E (https=)
RU (1) RU2341261C2 (https=)
TW (1) TWI287986B (https=)
WO (1) WO2003049734A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2499682A1 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo d + 5-fu/gemcitabine
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
RU2633266C2 (ru) * 2015-07-02 2017-10-11 Рауф Ашрафович Ашрафов Способ моделирования карциноидного синдрома
JP2025508846A (ja) * 2022-02-25 2025-04-10 アムリット・エンドゥ・インコーポレイテッド 疾患の治療のための経口オクトレオチド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) * 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
TWI287986B (en) 2007-10-11
PT1463504E (pt) 2006-10-31
NO332773B1 (no) 2013-01-14
IL162166A0 (en) 2005-11-20
DE60212710T2 (de) 2007-01-11
KR20040066893A (ko) 2004-07-27
HK1069983A1 (en) 2005-06-10
EP1463504A1 (en) 2004-10-06
PL369141A1 (en) 2005-04-18
TW200301113A (en) 2003-07-01
HUP0402537A3 (en) 2009-01-28
CN1602192A (zh) 2005-03-30
KR101010767B1 (ko) 2011-01-25
MXPA04005712A (es) 2004-12-06
HUP0402537A2 (hu) 2005-03-29
WO2003049734A1 (en) 2003-06-19
RU2004121687A (ru) 2005-08-10
US20050020647A1 (en) 2005-01-27
CY1105459T1 (el) 2010-04-28
ES2266610T3 (es) 2007-03-01
ATE330602T1 (de) 2006-07-15
JP2005511721A (ja) 2005-04-28
NO20042832L (no) 2004-07-05
DK1463504T3 (da) 2006-10-02
RU2341261C2 (ru) 2008-12-20
DE60212710D1 (de) 2006-08-03
US20060229345A1 (en) 2006-10-12
EP1463504B1 (en) 2006-06-21
AU2002366531A1 (en) 2003-06-23
BR0214917A (pt) 2004-11-30
CA2468994A1 (en) 2003-06-19
US20090246172A1 (en) 2009-10-01
NZ533378A (en) 2006-03-31
PL209147B1 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
US20090246172A1 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
US20110152329A1 (en) Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism
AU2002366531B2 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
CN111479572A (zh) Sstr靶向缀合物及其制剂
HK1069983B (en) Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome
ZA200404013B (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome.
AU2007200588A1 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
TW202606762A (zh) 治療t細胞淋巴瘤之組合物及方法
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
AU2007201437A1 (en) Combinations comprising epothilone derivatives and alkylating agents
HK1072723B (en) Combinations comprising an epothilone derivatives and an imidazotetrazinone
HK1080768B (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
EP1854464A2 (en) Combinations comprising epothilone derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100921

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110119

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140128

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees